Cartesian Therapeutics Inc (RNAC) Stock Price, Quote & News

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile derma...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 348 8698

Website: www.cartesiantherapeutics.com

Address:

7495 New Horizon Way, Frederick, United States

azv134 Dec. 4 at 3:04 PM

$RNAC Alright. Too cheap to ignore. Started a small position today and will continue buying.

1 · Reply

doDD22 Dec. 3 at 4:35 PM

$RNAC I was thinking about this again to since the last payment was March 2025 I believe AFTER fees the milestone payments will be around $0.15-0.40. Then depending on % royalties $0.20-0.80 once it hits the market. KRYS makes about 1B now and rules the market SEL212 is supposed to be safer with everyone on weight loss injections catching gout, we may have been at the right place right time a few years ago I sold out of RNAC a while ago since I wasn't ready to read new studies. These guys are all about buyouts so I wouldn't count them out but I'm not jumping back in since GME is so strong now lol

0 · Reply

ThomasTrainTrader Dec. 2 at 8:57 PM

$RNAC Carsten Brunn qualified to run a company? Or was he just picked because his name sounds close to “Cartesian”? 🤣

0 · Reply

ThomasTrainTrader Dec. 2 at 6:27 PM

$RNAC This is my biggest and only loser of 2025, down nearly 20% in the span of about a month lol, Carsten Brunn needs to take a $5 million dollar pay cut immediately since evidently the market doesn’t think that he can run a company. Thankfully my position is not huge

0 · Reply

kimgysen Dec. 2 at 3:54 PM

$RNAC And there goes 7 lol

1 · Reply

InjureReserve Dec. 1 at 11:01 PM

$RNAC somewhere between 175m-190m cvr, say 200m to be safe just in case. We’re not getting much if anything at all until FDA approval happens. My expectations are 0 until FDA approval. If we get FDA approval, To think we eventually get $2-$2.5 per CVR + whatever the math is per CVR on roughly ~10% royalty for the next 10+ years, we could be ok long term.

1 · Reply

Sky_Tree Nov. 28 at 10:06 PM

$RNAC On a more positive note, the next CVR payment should be in June and it should be quite chunky, maybe $1-2 per CVR I think? If that is correct, all those of us who are old investors and are currently way way down may be feeling a lot better. We live in hope…

1 · Reply

ThomasTrainTrader Nov. 26 at 11:10 PM

$RNAC Currently still down 13.5% from my avg of $8.75, my only net red position currently, down $15K

0 · Reply

kimgysen Nov. 26 at 4:10 PM

$RNAC This price will fizzle out to a typical -99.99% penny stock with a +99.99% chance yup

1 · Reply

OnlySurvivor Nov. 24 at 7:07 PM

$RNAC dead money 😩

0 · Reply

Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis

Oct 30, 2025, 7:05 AM EDT - 5 weeks ago

Cartesian Therapeutics Announces New Employment Inducement Grants

Oct 3, 2025, 7:05 AM EDT - 2 months ago

Cartesian Therapeutics Announces New Employment Inducement Grant

Sep 9, 2025, 7:09 PM EDT - 3 months ago

Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:00 AM EDT - 3 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Aug 7, 2025, 10:52 AM EDT - 4 months ago

Cartesian (RNAC) Q2 Revenue Drops 99%

May 30, 2025, 7:00 AM EDT - 6 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025, 7:00 AM EDT - 7 months ago

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 8, 2025, 7:00 AM EDT - 8 months ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Jan 27, 2025, 7:00 AM EST - 11 months ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Dec 3, 2024, 6:00 AM EST - 1 year ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Nov 21, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Nov 10, 2024, 12:26 PM EST - 1 year ago

Cartesian Therapeutics: Uncertainty Remains

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Sep 17, 2024, 9:45 AM EDT - 1 year ago

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 12:55 PM EDT - 1 year ago

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 2, 2024, 6:40 AM EDT - 1 year ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:30 AM EDT - 1 year ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 13, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 8, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 7, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

azv134 Dec. 4 at 3:04 PM

$RNAC Alright. Too cheap to ignore. Started a small position today and will continue buying.

1 · Reply

doDD22 Dec. 3 at 4:35 PM

0 · Reply

ThomasTrainTrader Dec. 2 at 8:57 PM

$RNAC Carsten Brunn qualified to run a company? Or was he just picked because his name sounds close to “Cartesian”? 🤣

0 · Reply

ThomasTrainTrader Dec. 2 at 6:27 PM

0 · Reply

kimgysen Dec. 2 at 3:54 PM

$RNAC And there goes 7 lol

1 · Reply

InjureReserve Dec. 1 at 11:01 PM

1 · Reply

Sky_Tree Nov. 28 at 10:06 PM

1 · Reply

ThomasTrainTrader Nov. 26 at 11:10 PM

$RNAC Currently still down 13.5% from my avg of $8.75, my only net red position currently, down $15K

0 · Reply

kimgysen Nov. 26 at 4:10 PM

$RNAC This price will fizzle out to a typical -99.99% penny stock with a +99.99% chance yup

1 · Reply

OnlySurvivor Nov. 24 at 7:07 PM

$RNAC dead money 😩

0 · Reply

ThomasTrainTrader Nov. 19 at 9:01 PM

$RNAC $RNAC genuine congrats to everyone who shorted this company, who coulda thunk it would go down another 20% from all time lows in the span of 1 month. It’s actually insane, however m I’m still gonna hold until something proves that this stock is as cooked as the market is pricing it as

0 · Reply

ThomasTrainTrader Nov. 19 at 6:21 PM

$RNAC This stock really is just non stop down huh? Definitely made a mistake entering around $9, I still have a conviction that this will reach $14 region but it may take longer than I expected (or perhaps never). Seems like it’s just destined to bleed until insiders do something to bolster confidence

2 · Reply

JarvisFlow Nov. 19 at 12:38 PM

HC Wainwright & Co. has adjusted their stance on Cartesian Therapeutics ( $RNAC ), setting the rating to Buy with a target price of 40 → 30.

0 · Reply

ThomasTrainTrader Nov. 18 at 12:08 AM

$RNAC Short interest is current at ~22%, super high even for clinical companies it actually does help to explain the exaggerated selling recently. There are simply almost no institutional buyers at the moment so combined with additional short pressure it can only reasonably lead to a gradual dissolution of the price floor

0 · Reply

StockFactz Nov. 17 at 8:02 PM

$RNAC This bs is basically at all time lows right? Excluding that massive -20% dip to $5.98 on like 100 share volume 😂😂😂😂. What the f*ck Carsten

0 · Reply

doDD22 Nov. 15 at 2:38 PM

$RNAC I wouldn’t necessarily count them out Springer is interested in buyouts But that won’t happen until 20+ which may take some time Or drug approval I no longer have a position Just selb cvrs Left because I didn’t want to dig into new trial But from what I remember rnac does have some production capabilities which could prove to be valuable

0 · Reply

JarvisFlow Nov. 14 at 1:11 PM

BTIG updates rating for Cartesian Therapeutics ( $RNAC ) to Buy, target set at 42 → 44.

0 · Reply

4976f2e Nov. 13 at 9:25 PM

$RNAC Interesting https://www.globenewswire.com/news-release/2025/11/13/3187838/0/en/Cartesian-Therapeutics-Announces-Strong-Efficacy-Signal-in-Phase-2-Trial-of-Descartes-08-in-Patients-with-SLE-and-Expansion-of-Clinical-Development-into-Myositis.html

0 · Reply

StockFactz Nov. 13 at 6:43 PM

$RNAC What the f*ck is wrong with this company, might just sell here at a 10% loss

1 · Reply

EmbryonicJourney Nov. 12 at 5:26 PM

$RNAC Looking at the YTD graph is just depressing. Can someone remind me, how come we went from $20 to $10 in 3 months at the start of the year

1 · Reply

StockFactz Nov. 11 at 6:42 PM

$RNAC All bio tech stocks ripping today and this shit is barely up 😂 what is this company doing

0 · Reply

kimgysen Nov. 10 at 9:24 PM

$RNAC Probably lost 10$ at this point

0 · Reply

Market Cap	178.91M
Revenue (ttm)	38.91M
Net Income (ttm)	-77.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-198.97%
Debt to Equity Ratio	0.00

Volume	126,100
Avg Vol	136,066
Day's Range	N/A - N/A
Shares Out	26.00M
Stochastic %K	29%
Beta	0.36
Analysts	Strong Sell
Price Target	$35.28